[590-S].
590-S (1-phthalidyl-5-fluorouracil) is a derivative of 5-fluorouracil and shows a several characteristics in experimental studies. That is, good absorption from the intestine, high blood levels of 5-fluorouracil, its rapid clearance, low toxicities, excellent tumor inhibition and broad anticancer spectrum, etc. From preliminary studies and phase I studies, MTD is thought to be 750-800 mg/m2 in daily administration. Mild G.I. toxicities was encountered in a few cases. However, CNS toxicities were not experienced in any of our cases.
D000284:Administration, Oral; D000328:Adult; D000818:Animals; D000855:Anorexia / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D007942:Leukemia, Experimental / Q000188:drug therapy / Q000378:metabolism; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy / Q000378:metabolism; D008297:Male; D051379:Mice; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000378:metabolism; D011817:Rabbits; D051381:Rats; D012513:Sarcoma, Experimental / Q000188:drug therapy / Q000378:metabolism; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000378:metabolism
D000970:Antineoplastic Agents; C043972:1-phthalidyl-5-fluorouracil; D005472:Fluorouracil